{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:25:42Z","timestamp":1778736342382,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901713"],"award-info":[{"award-number":["81901713"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-11557-6","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T14:01:01Z","timestamp":1744380061000},"page":"6564-6574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hepatic arterial infusion chemotherapy versus transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study"],"prefix":"10.1007","volume":"35","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxv","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruibing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2753-6928","authenticated-orcid":false,"given":"Ketao","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"11557_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"11557_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G (2019) Cholangiocarcinoma: epidemiology and risk factors. Liver Int 39:19\u201331","journal-title":"Liver Int"},{"key":"11557_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","volume":"145","author":"S Rizvi","year":"2013","unstructured":"Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145:1215\u20131229","journal-title":"Gastroenterology"},{"key":"11557_CR4","doi-asserted-by":"publisher","first-page":"102336","DOI":"10.1016\/j.eclinm.2023.102336","volume":"67","author":"C Pang","year":"2024","unstructured":"Pang C, Li J, Dou J et al (2024) Microwave ablation versus liver resection for primary intrahepatic cholangiocarcinoma within Milan criteria: a long-term multicenter cohort study. eClinicalMedicine 67:102336","journal-title":"eClinicalMedicine"},{"key":"11557_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/jso.23605","volume":"110","author":"N Amini","year":"2014","unstructured":"Amini N, Ejaz A, Spolverato G et al (2014) Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol 110:163\u2013170","journal-title":"J Surg Oncol"},{"key":"11557_CR6","doi-asserted-by":"publisher","first-page":"102258","DOI":"10.1016\/j.ctrv.2021.102258","volume":"99","author":"J Edeline","year":"2021","unstructured":"Edeline J, Lamarca A, McNamara MG et al (2021) Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev 99:102258","journal-title":"Cancer Treat Rev"},{"key":"11557_CR7","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA et al (2016) Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v28\u2013v37","journal-title":"Ann Oncol"},{"key":"11557_CR8","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268\u20131289","journal-title":"J Hepatol"},{"key":"11557_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"D Alvaro","year":"2023","unstructured":"Alvaro D, Gores GJ, Walicki J et al (2023) EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol 79:181\u2013208","journal-title":"J Hepatol"},{"key":"11557_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/hbsn.2016.11.02","volume":"6","author":"LJ Savic","year":"2017","unstructured":"Savic LJ, Chapiro J, Geschwind J-FH (2017) Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatobiliary Surg Nutr 6:7\u201321","journal-title":"Hepatobiliary Surg Nutr"},{"key":"11557_CR11","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734\u20131739","journal-title":"Lancet"},{"key":"11557_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3350\/cmh.2023.0202","volume":"29","author":"Y Cho","year":"2023","unstructured":"Cho Y, Choi JW, Kwon H et al (2023) Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association. Clin Mol Hepatol 29:521\u2013541","journal-title":"Clin Mol Hepatol"},{"key":"11557_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000487608","volume":"7","author":"P-Y Chang","year":"2018","unstructured":"Chang P-Y, Huang C-C, Hung C-H et al (2018) Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment. Liver Cancer 7:312\u2013322","journal-title":"Liver Cancer"},{"key":"11557_CR14","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3390\/cancers15082384","volume":"15","author":"M Owen","year":"2023","unstructured":"Owen M, Makary MS, Beal EW (2023) Locoregional therapy for intrahepatic cholangiocarcinoma. Cancers (Basel) 15:2384","journal-title":"Cancers (Basel)"},{"key":"11557_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1200\/JCO.1984.2.6.595","volume":"2","author":"N Kemeny","year":"1984","unstructured":"Kemeny N, Daly J, Oderman P et al (1984) Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 2:595\u2013600","journal-title":"J Clin Oncol"},{"key":"11557_CR16","doi-asserted-by":"publisher","first-page":"1270264","DOI":"10.3389\/fgstr.2023.1270264","volume":"2","author":"MA Cocozza","year":"2023","unstructured":"Cocozza MA, Braccischi L, De Cinque A et al (2023) Unresectable intrahepatic cholangiocarcinoma: TARE or TACE, which one to choose? Front Gastroenterol 2:1270264","journal-title":"Front Gastroenterol"},{"key":"11557_CR17","doi-asserted-by":"publisher","first-page":"1234342","DOI":"10.3389\/fphar.2023.1234342","volume":"14","author":"Z Yang","year":"2023","unstructured":"Yang Z, Fu Y, Wu W et al (2023) Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma. Front Pharm 14:1234342","journal-title":"Front Pharm"},{"key":"11557_CR18","doi-asserted-by":"publisher","first-page":"611118","DOI":"10.3389\/fonc.2021.611118","volume":"11","author":"Z Cai","year":"2021","unstructured":"Cai Z, He C, Zhao C, Lin X (2021) Survival comparisons of hepatic arterial infusion chemotherapy with mFOLFOX and transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma. Front Oncol 11:611118","journal-title":"Front Oncol"},{"key":"11557_CR19","first-page":"57","volume":"9","author":"China Research Hospital Association","year":"2023","unstructured":"China Research Hospital Association (2023) Expert consensus of Chinese biliary tract tumor multidisciplinary treatment. J Multidiscip Cancer Manag 9:57\u201368","journal-title":"J Multidiscip Cancer Manag"},{"key":"11557_CR20","first-page":"243","volume":"102","author":"Chinese Association of Hepatocellular Carcinoma, Liver Cancer Professional Committee","year":"2022","unstructured":"Chinese Association of Hepatocellular Carcinoma, Liver Cancer Professional Committee (2022) Clinical practice guidelines for hepatocellular carcinoma with portal vein tumor thrombus (2021 edition). Chin Med J 102:243\u2013254","journal-title":"Chin Med J"},{"key":"11557_CR21","doi-asserted-by":"crossref","unstructured":"Jiang N, Zhang Z, Yin X et al (2024) Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study. Radiol Med 129:631\u2013642","DOI":"10.1007\/s11547-024-01781-3"},{"key":"11557_CR22","unstructured":"US Department of Health and Human Services (2017) Common terminology criteria for adverse events (CTCAE) version 5.0. Available via https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 15 Jan 2025"},{"key":"11557_CR23","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/j.jvir.2010.08.015","volume":"21","author":"L Yang","year":"2010","unstructured":"Yang L, Zhang XM, Zhou XP et al (2010) Correlation between tumor perfusion and lipiodol deposition in hepatocellular carcinoma after transarterial chemoembolization. J Vasc Interv Radiol 21:1841\u20131846","journal-title":"J Vasc Interv Radiol"},{"key":"11557_CR24","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.jhep.2021.07.016","volume":"75","author":"G Carpino","year":"2021","unstructured":"Carpino G, Cardinale V, Di Giamberardino A et al (2021) Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. J Hepatol 75:1377\u20131386","journal-title":"J Hepatol"},{"key":"11557_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"Q-J Li","year":"2022","unstructured":"Li Q-J, He M-K, Chen H-W et al (2022) Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol 40:150\u2013160","journal-title":"J Clin Oncol"},{"key":"11557_CR26","first-page":"59","volume":"6","author":"N Ge","year":"2023","unstructured":"Ge N, Wang H, He C et al (2023) Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE? J Interv Med 6:59\u201363","journal-title":"J Interv Med"},{"key":"11557_CR27","first-page":"198","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C et al (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 73:198\u2013222","journal-title":"CA Cancer J Clin"},{"key":"11557_CR28","doi-asserted-by":"crossref","unstructured":"Liu B, Gao S, Guo J et al (2024) Efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy as the second-line treatment in advanced hepatocellular carcinoma. J Hepatocell Carcinoma 11:477\u2013488","DOI":"10.2147\/JHC.S452120"},{"key":"11557_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3350\/cmh.2022.0391","volume":"29","author":"H Iwamoto","year":"2023","unstructured":"Iwamoto H, Shimose S, Shirono T et al (2023) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. Clin Mol Hepatol 29:593\u2013604","journal-title":"Clin Mol Hepatol"},{"key":"11557_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jjco\/hyq145","volume":"41","author":"M Kondo","year":"2011","unstructured":"Kondo M, Morimoto M, Numata K et al (2011) Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Jpn J Clin Oncol 41:69\u201375","journal-title":"Jpn J Clin Oncol"},{"key":"11557_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00280-009-1126-2","volume":"65","author":"HY Woo","year":"2010","unstructured":"Woo HY, Bae SH, Park JY et al (2010) A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharm 65:373\u2013382","journal-title":"Cancer Chemother Pharm"},{"key":"11557_CR32","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/sj.bjc.6601329","volume":"89","author":"SJ Wigmore","year":"2003","unstructured":"Wigmore SJ, Redhead DN, Thomson BNJ et al (2003) Postchemoembolisation syndrome\u2014tumour necrosis or hepatocyte injury? Br J Cancer 89:1423\u20131427","journal-title":"Br J Cancer"},{"key":"11557_CR33","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.3390\/cancers13123091","volume":"13","author":"C Laface","year":"2021","unstructured":"Laface C, Laforgia M, Molinari P et al (2021) Hepatic arterial infusion of chemotherapy for advanced hepatobiliary cancers: state of the art. Cancers (Basel) 13:3091","journal-title":"Cancers (Basel)"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11557-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11557-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11557-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:06:45Z","timestamp":1757498805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11557-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["11557"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11557-6","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is KeTao Mu.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required for this study because the study adopted a retrospective study design.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethical Review Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}